Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (KVUE) reports developments as a pure-play consumer health company with a brand portfolio that includes Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its updates center on consumer health categories, operating and financial results, and board actions such as cash dividends on common stock.
Recurring news themes also include material agreements, capital-structure matters, governance changes, shareholder voting topics and consumer-health regulatory disclosures. The coverage reflects Kenvue’s role as a public company operating branded everyday-care products across personal care, oral care, pain management and related health categories.
Kenvue (NYSE: KVUE) has appointed Amit Banati as its new Chief Financial Officer, effective May 12, 2025. Banati, a 30-year veteran in consumer products finance and operations, will succeed Paul Ruh and oversee Finance and Strategy functions. Banati joins from Kellanova (previously Kellogg Company) where he served as Vice Chairman and CFO, with prior experience at Kraft Foods, Cadbury Schweppes, and Procter & Gamble.
The new CFO brings significant international operations experience, particularly in Asia Pacific, Middle East, India, and Africa. His focus will be on supporting revenue growth through data management, resource allocation, margin improvement, strengthening cash flow, and fostering greater agility in business planning and financial forecasting.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, before market open. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results.
Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event.
Kenvue's portfolio includes renowned brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol, which are science-backed and recommended by healthcare professionals globally.
Kenvue (NYSE: KVUE) has announced a quarterly dividend declaration approved by its Board of Directors. The company will pay a dividend of $0.205 per share on its common stock. The dividend will be distributed on May 28, 2025, to shareholders who are recorded on the company's books at the close of business on May 14, 2025.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, has announced a five-year collaboration with Microsoft to transform its digital operations through advanced AI technologies. The partnership will leverage Microsoft Azure's capabilities in machine-enabled collaboration, predictive analytics, smart agents, digital twins, and generative AI.
The collaboration aims to:
- Accelerate product development and optimize clinical research data
- Advance data-driven market strategies and personalize consumer experiences
- Enhance retail excellence through algorithmic selling and improved inventory management
- Optimize business processes for new growth opportunities
Kenvue is already piloting Microsoft Azure AI, Microsoft 365 Copilot, and Copilot Studio integration across supply chain, operations, and content creation functions.
Kenvue Inc. (NYSE: KVUE) has announced actress and entrepreneur Shay Mitchell as the first global brand ambassador for OGX® Haircare. Mitchell will represent the brand's Fixer character in a new 360° campaign promoting the OGX® Bond Protein Repair line.
The campaign features Mitchell alongside Trichologist Abbey Yung, highlighting solutions for hair damage through television spots and a #DamageDetected social media series. The new product line includes a Bond Protein Repair 450°F Heat Protect Spray, formulated with a patented bond-building protein to repair and protect hair at a lower price point than salon brands.
According to Andrew Stanleick, President of Skin Health & Beauty at Kenvue, 8 in 10 people experience hair damage. The campaign aims to address these concerns with science-backed repair solutions. OGX® currently holds the position of #1 in hair repair based on market data through November 2024.
Kenvue Inc. (NYSE: KVUE) has launched the new Neutrogena® Ultra Sheer® Face Liquid Mineral Sunscreen SPF 70, addressing key consumer barriers to daily sunscreen use. According to a December 2024 company study, 99% of healthcare providers believe better application and aesthetic experiences would increase patient sunscreen usage.
The company has partnered with John Cena and dermatologist Dr. Neera Nathan for the 'Sunscreen You Can't See' campaign, leveraging Cena's 'You Can't See Me' catchphrase to highlight the product's invisible finish. The sunscreen features Helioplex® and Purescreen® Technology for broad-spectrum UVA/UVB protection.
Neutrogena® is expanding its sun safety initiatives in 2025 as the official sun care sponsor of Coachella, Stagecoach Festival, and the World Surf League. The brand is also strengthening its partnership with the Melanoma Research Foundation, surpassing $1 million in total donations, and launching the Sun Safety for All educational program.
Kenvue Inc. (NYSE: KVUE) has officially opened its new 290,000 sq. ft. global headquarters in Summit, New Jersey, relocating from Skillman. The facility includes a 100,000 sq. ft. state-of-the-art Science and Innovation Lab and features several specialized areas: The Insights Lab, Virtual Experience Room with 270-degree digital retail environment, Sensory Lab for rapid prototyping, Design Lab for 3D/2D modeling, and The Company Store.
The LEED Gold certified headquarters consolidates teams previously spread across seven U.S. locations, positioning itself near major talent hubs in life science, data, technology, and marketing. The maker of iconic brands like Neutrogena®, Listerine®, Aveeno®, and Tylenol® aims to foster innovation and enhance consumer experiences through this new facility.
Kenvue Inc. (NYSE: KVUE) will present new clinical data from 14 studies at the 2025 American Academy of Dermatology Annual Meeting in Orlando, showcasing innovations in skin health and beauty products. The research focuses on their brands including Neutrogena® and Aveeno®.
Key findings include:
- Neutrogena® Collagen Bank's twice-daily use reduces collagen loss and improves skin qualities
- The 'open sandwich' method with Neutrogena® Hydro Boost Water Cream optimizes hydration for sensitive skin
- Aveeno® baby products improve infant skin hydration and barrier integrity
- Oat flour in Aveeno® products increases hyaluronic acid production by 43%
- New Neutrogena® Ultra Sheer Mineral Face Liquid SPF 70 provides 3x more UVA protection with 30% less whitening versus competitors
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, has announced three new appointments to its Board of Directors. Sarah Hofstetter, President of Profitero, and Erica Mann, former President of Bayer's Consumer Health Division, join as independent directors, while Jeffrey Smith from Starboard Value LP also joins the board.
The appointments are part of a cooperation agreement with Starboard Value LP. Hofstetter will serve on the Audit Committee, Mann on the Nominating, Governance & Sustainability Committee, and Smith on the Compensation & Human Capital Committee. The board will temporarily expand from 11 to 14 directors, reducing to 13 at the 2025 Annual Meeting.
As part of the agreement, Starboard will withdraw its nominated director candidates and vote in favor of Kenvue's Board nominees at the 2025 Annual Meeting.